Nimenrix IM Injection

Nimenrix IM Injection 0.5 ml/prefilled syringe

Meningococcal conjugate vaccine (MCV) is a vaccine used to prevent infection caused by certain strains of Neisseria meningitidis, a type of bacteria that can cause meningitis and septicemia (an infection of the blood). This vaccine is administered to children beginning at age 12 months. MCV is made from components of the meningococcal bacteria and has been shown to be very effective at preventing serious illness due to the bacteria.

Uses for

The meningococcal conjugate vaccine is primarily intended to prevent the occurrence of meningitis and septicemia caused by four out of the five major serogroups (A, C, W, and Y). The vaccine can also reduce the severity of illness in individuals who do become infected by these bacteria.

Brand Name	Nimenrix
Type	IM Injection
Weight	0.5 ml/prefilled syringe
Generic	Meningococcal Conjugate Vaccine
Manufacturer	Radiant Pharmaceuticals Ltd. (Mfg. by: Pfizer)
Available in	English বাংলা

Mechanism of Action

The meningococcal conjugate vaccine is made up of four components of the actual bacteria: O-acetylated capsular polysaccharide, N-acetylated capsular polysaccharide, lipopolysaccharide, and the N-terminal domain of the surface protein PorA. When this vaccine is injected into the body, it stimulates the immune system to produce antibodies that recognize and fight off the bacteria that can cause meningitis or septicemia.

How Long Does it Take to Work?

The meningococcal conjugate vaccine typically produces an immune response within two weeks after the initial dose. For maximum protection, additional booster shots of the vaccine are recommended at around age 11, 12, and 15-18.

Absorption

The meningococcal conjugate vaccine is absorbed rapidly and completely after injection.

Route of Elimination

The meningococcal conjugate vaccine is rapidly metabolized and eliminated from the body through the kidneys.

Dosage

Posology: Meningococcal Conjugate Vaccine should be used in accordance with available official recommendations. Primary immunisation:

Infants from 6 weeks to less than 6 months of age: two doses, each of 0.5 ml, should be administered with an interval of 2 months between doses.
Infants from 6 months of age, children, adolescents and adults: a single 0.5 mL doseshould be administered.
An additional primary dose of Meningococcal Conjugate Vaccine may be considered appropriate for some individuals.

Booster doses: After completion of the primary immunisation course in infants 6 weeks to less than 12 months of age, a booster dose should be given at 12 months of age with an interval of at least 2 months after the last Meningococcal Conjugate vaccination. In previously vaccinated individuals 12 months of age and older, Meningococcal Conjugate Vaccine may be given as a booster dose if they have received primary vaccination with a conjugated or plain polysaccharide meningococcal vaccine.

The dosage of the meningococcal conjugate vaccine depends on the patient's age and the manufacturer of the vaccine. Generally, it is recommended for children starting at ages 12 months and up to, and including, 10 years. The usual dose is 0.5mL given as a single intramuscular (IM) injection. For adolescents aged 11-18, the dose is 0.5 mL given as a single IM injection.

Administration

The meningococcal conjugate vaccine is usually given as an intramuscular injection into the upper arm of the patient. It should be administered by a healthcare professional.

Side Effect

The most common side effects of the meningococcal conjugate vaccine include pain, redness, and swelling at the injection site, as well as headache, body aches, and flu-like symptoms.

Toxicity

The meningococcal conjugate vaccine is generally safe and well-tolerated. However, like any other vaccine, it can occasionally result in serious side effects such as an allergic reaction or an autoimmune disorder.

Precaution

The meningococcal conjugate vaccine should not be given to anyone with a known history of anaphylaxis or a severe allergic reaction after a previous dose of the vaccine. It is also important to tell your healthcare provider if you are pregnant or breastfeeding.

Interactions

The meningococcal conjugate vaccine should not be used in combination with any other vaccine. Also, it should not be given to anyone who is receiving any other type of treatment, such as antibiotics, steroids, or chemotherapy.

Disease Interaction

The meningococcal conjugate vaccine should not be given to patients with certain medical conditions that are known to weaken the immune system. These conditions include HIV/AIDS, cancer, leukemia, lymphoma, and other immunodeficiency disorders.

Drug Interaction

The meningococcal conjugate vaccine may interact with certain drugs such as antibiotics, steroids, or immunosuppressants. Patients who are taking any of these medications should inform their healthcare provider before receiving the vaccine.

Food Interactions

The meningococcal conjugate vaccine should not be taken with food and should be injected on an empty stomach.

Pregnancy Use

The safety and effectiveness of the vaccine in pregnant women has not been established. For the safest outcome, pregnant women should consult their healthcare provider before receiving the vaccine.

Lactation Use

The safety and effectiveness of the meningococcal conjugate vaccine when given to nursing mothers has not been established. For the safest outcome, nursing mothers should consult their healthcare provider before receiving the vaccine.

Acute Overdose

The risk of an acute overdose of the meningococcal conjugate vaccine is extremely low, because the dose is very small. However, if it is suspected that an overdose has occurred, the patient should be monitored for any adverse effects and medical attention should be sought as soon as possible.

Contraindication

The meningococcal conjugate vaccine should not be given to anyone with a known history of anaphylaxis or a severe allergic reaction after a previous dose of the vaccine. It should also not be given to people with certain medical conditions such as a suppressed immune system, bleeding disorders, or kidney disease. Finally, it should not be given to anyone who is undergoing treatment with corticosteroids, immunosuppressants, or other types of medications.

Use Direction

The meningococcal conjugate vaccine should be administered by a healthcare professional as a single intramuscular injection in the upper arm of the patient. The dosage depends on the patient's age and the manufacturer of the vaccine.

Storage Condition

The meningococcal conjugate vaccine should be stored at room temperature between 2°C and 8°C. It should not be exposed to exposure to direct sunlight or freezing temperatures.